Precision BioSciences Inc. Form 8-K Summary
Business Context and Reporting Period
Precision BioSciences, Inc. (DTIL) filed a Current Report on Form 8-K on March 12, 2026. The filing announces the company's financial results for the quarter and full year ended December 31, 2025. The detailed results are contained in a press release furnished as Exhibit 99.1.
Key Financial Metrics
The provided filing text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being included in the attached press release (Exhibit 99.1) but are not present in the 8-K cover document itself.
Material Changes
The filing text does not provide specific data regarding material changes versus the prior comparable period. Investors must refer to the incorporated press release for comparative analysis.
Guidance, Outlook, and Risks
The filing text does not include specific guidance, outlook, management commentary, risks, contingencies, or unusual items. The document serves primarily as a notification that the results have been issued and directs readers to the press release for full details.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for actual revenue, net loss, and cash burn figures for Q4 and FY 2025.
- Verify year-over-year growth or decline in key operational metrics not listed in this summary.
- Check for updated forward-looking guidance or cash runway projections in the press release.
- Confirm any new material agreements or clinical trial updates mentioned in the full announcement.